Prospective Study regarding the Safety of a Periprocedual Anticoagulation Regimen with Direct Oral Anticoagulant (DOAC) Other than Dabigatran in the Patients Undergoing Catheter Ablation for Paroxysmal or Persistent Atrial Fibrillation. - SWITCH Dabigatran

Shonankamakura General Hospital Department of Cardiology0 个研究点目标入组 121 人开始时间: 2017年9月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with a history of hypersensitivity to components of Prazaxa capsules 2) Patients with hemorrhagic symptoms, patients with hemorrhagic diathesis and patients with hemostatic disorder 3) Patients with COPD and severe respiratory disease 4) Patients with advanced renal injury including dialysis patients (creatinine clearance less than 30 mL / min) 5) Patients with severe liver disease (AST (GOT) or ALT (GPT)> 100 U) 6) Women who may be pregnant or have a possibility of pregnancy 7) Women who are breastfeeding 8) Patients who are diagnosed as having a life expectancy of less than half a year 9) Patients who received other test drugs or investigational drugs within 3 months before the start of administration of study drug 10) Patients with organic lesions at risk of clinically serious bleeding (including hemorrhagic stroke within 6 months) 11) Patients who have indwelling spinal and epidural catheters and patients within 1 hour after removal 12) Patients receiving itraconazole (oral preparation) 13) Patients with cryoglobulinemia 14) In addition, patients who are deemed inappropriate as research subjects by research managers

发起方

Shonankamakura General Hospital Department of Cardiology